Mandate

VINGE ADVISES TOBII IN CONNECTION WITH THE LISTING ON NASDAQ STOCKHOLM

April 28, 2015

Vinge advises Tobii AB (publ) in connection with Tobii’s listing on Nasdaq Stockholm.

Tobii is the global leader in eye tracking, a technology that is used to gain insights in human behavior or as a means to interact with computers and other devices. The Swedish language prospectus was published on 13 April 2015 and the first day of trading was 24 April 2015. The offering price has been set at SEK 25 per share, corresponding to a market value of Tobii of approximately SEK 2.1 billion.

Vinge’s team primarily consisted of Jesper Schönbeck, Johan Winnerblad, Rikard Lindahl, Charlotta Järnstedt and Henrik Wastenson.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025